# US 2023/0054612 A1 · Fusokines involving cytokines with strongly reduced receptor binding affinities

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0054612 A1
- Document ID: US20230054612A1
- Status: Published application
- Kind: A1
- Application number: 17/733,026
- Filed: 2022-04-29
- Published: 2023-02-23
- Earliest claimed: 2013-07-18
- Assignees: Vib Vzw; Universiteit Gent; Centre National de le Recherche Scientifique; Universite De Montpellier; Centre Hospitalier Regional Universitaire De Montpellier
- Applicants: Vib Vzw; Universiteit Gent; Centre National De Le Recherche Scientifique; Université De Montpellier; Centre Hospitalier Regional Universitaire de Montpellier
- Inventors: Jan TAVERNIER; Jennyfer BULTINCK; Sarah GERLO; Gilles UZE; Franciane PAUL; Yann BORDAT
- Web page: https://patentgrep.com/patent/US20230054612A1

## CPC

- C07K 14/521: {Chemokines}
- A61K 38/195: {Chemokines, e.g. RANTES}
- A61K 38/2006: {IL-1}
- A61P 37/04: Immunostimulants
- C07K 14/52: Cytokines; Lymphokines; Interferons
- C07K 14/523: {Beta-chemokines, e.g. RANTES, I-309/TCA-3, MIP-1alpha, MIP-1beta/ACT-2/LD78/SCIF, MCP-1/MCAF, MCP-2, MCP-3, LDCF-1, LDCF-2}
- C07K 14/525: Tumour necrosis factor [TNF]
- C07K 14/545: IL-1
- C07K 14/56: IFN-alpha
- C07K 14/5759: {Products of obesity genes, e.g. leptin, obese (OB), tub, fat}
- A61K 38/19: Cytokines; Lymphokines; Interferons
- A61K 38/2264: {Obesity-gene products, e.g. leptin}
- C07K 2319/00: Fusion polypeptide
- C07K 2319/33: fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
- C07K 2319/74: containing a fusion for binding to a cell surface receptor
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to a fusion protein comprising at least two cytokines, of which at least one is a modified cytokine with a strongly reduced binding affinity to its receptor, or to one of its receptors. Preferably, both cytokines are connected by a linker, preferably a GGS linker. The invention relates further to said fusion protein for use in treatment of diseases.

## Claims

### Claim 1

A fusion protein comprising at least two cytokines, of which at least one cytokine is modified in such a way that it has a strongly reduced binding activity to its receptor,

### Claim 2 (depends on 1)

The fusion protein according to claim 1, further comprising a GGS linker.

### Claim 3 (depends on 1)

The fusion protein according to claim 1, wherein said cytokines are XCL1 and IFNa2.

### Claim 4 (depends on 1)

The fusion protein according to claim 1, wherein said cytokines are CCL20 and ILβ.

### Claim 5 (depends on 1)

The fusion protein according to claim 1, wherein said cytokines are TNF and leptin.

### Claim 6

(canceled)

### Claim 7 (depends on 1)

A method of treating cancer comprising administering to a subject in need thereof a fusion protein according to claim 1.

### Claim 8 (depends on 1)

A method of modulating an immune response comprising administering to a subject in need thereof a fusion protein according to claim 1.
